AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35129789 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication reconciliation and medication review conducted by study pharmacists in addition to standard care
Number of subjects: 402
Study 35129789 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 402
Study 32950693 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide (6.25 mg/kg every 6 hours, administered as a 2-hour i.v. infusion, for a minimum of 21 days or until resolution of VOD/SOS signs and symptoms)
Number of subjects: 1000
Study 32950693 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide (25 mg/kg/day in phase 2 study)
Number of subjects: 1000
Study 32950693 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide (in T-IND)
Number of subjects: 1000
Study 32950693 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide (in pooled phase 2 and 3 studies)
Number of subjects: 1000
Study 36197920 — intervention group
Group type: EXPERIMENTAL
Intervention: modified directly observed therapy (mDOT)
Number of subjects: 147
Study 36197920 — intervention group
Group type: COMPARATOR
Intervention: standard individual therapy (SIT)
Number of subjects: 147
Study 36197920 — intervention group
Group type: EXPERIMENTAL
Intervention: groups therapy (GT)
Number of subjects: 147
Study 34011310 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 184
Study 34011310 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 184
Study 34611892 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified therapy with aspirin 100 mg once daily in combination with clopidogrel 150 mg once daily
Number of subjects: 434
Study 34611892 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified therapy with aspirin 100 mg once daily in combination with clopidogrel 75 mg once daily plus cilostazol 100 mg twice daily
Number of subjects: 434
Study 34611892 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified therapy with aspirin 100 mg once daily in combination with ticagrelor 90 mg twice daily
Number of subjects: 434
Study 34611892 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy with clopidogrel 75 mg once daily (STD)
Number of subjects: 434
Study 34611892 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified therapy (all combinations)
Number of subjects: 434
Study 34245031 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized estimating equation (GEE) approach for sample size determination
Number of subjects: 0
Study 34245031 — intervention group
Group type: COMPARATOR
Intervention: Conventional method for sample size determination
Number of subjects: 0
Study 34245031 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed GEE sample size method
Number of subjects: 0
Study 34245031 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-based approach
Number of subjects: 0
Study 32129263 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% mannitol
Number of subjects: 30
Study 32129263 — intervention group
Group type: COMPARATOR
Intervention: 3% hypertonic saline (HTS)
Number of subjects: 30
Study 35588336 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ventral mesh rectopexy (LVMR)
Number of subjects: 28
Study 33849821 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziyin recipe
Number of subjects: 0
Study 33849821 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (CC and HMG)
Number of subjects: 0
Study 36417652 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping combined with a 4-week neck exercise program (n=29)
Number of subjects: 60
Study 32212856 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine with cognitive training
Number of subjects: 100
Study 32212856 — intervention group
Group type: COMPARATOR
Intervention: Placebo with cognitive training
Number of subjects: 100
Study 32212856 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Vortioxetine and Placebo)
Number of subjects: 100
Study 36470716 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printing models (3Dp)
Number of subjects: 100
Study 36470716 — intervention group
Group type: COMPARATOR
Intervention: Control group (without 3Dp models)
Number of subjects: 100
Study 34299775 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) - 10 × 1-min cycling at VO2peak power output
Number of subjects: 25
Study 34644389 — intervention group
Group type: EXPERIMENTAL
Intervention: iCanQuit
Number of subjects: 169
Study 34644389 — intervention group
Group type: COMPARATOR
Intervention: QuitGuide
Number of subjects: 169
Study 32138563 — intervention group
Group type: EXPERIMENTAL
Intervention: β-Alanine (BA) supplementation (12 g·day‐1 for 14 days)
Number of subjects: 19
Study 32138563 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 19
Study 35377934 — intervention group
Group type: EXPERIMENTAL
Intervention: PDL injection and alternative palatal infiltration
Number of subjects: 133
Study 35377934 — intervention group
Group type: COMPARATOR
Intervention: Mock PDL injection and conventional palatal infiltration
Number of subjects: 133
Study 33982892 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically determined fasting insulin concentrations
Number of subjects: 360453
Study 33982892 — intervention group
Group type: EXPERIMENTAL
Intervention: Outlier-corrected fasting insulin concentrations
Number of subjects: 360453
Study 33982892 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable MR analyses adjusted for BMI
Number of subjects: 360453
Study 33982892 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic scores for fasting insulin
Number of subjects: 360453
Study 33982892 — intervention group
Group type: EXPERIMENTAL
Intervention: Gout risk
Number of subjects: 360453
Study 33051075 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamer-Irrigator-Aspirator (RIA) at a diameter of 4.0 mm larger than isthmus
Number of subjects: 45
Study 33051075 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamer-Irrigator-Aspirator (RIA) at a diameter of 2.5 mm larger than isthmus
Number of subjects: 45
Study 33051075 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamer-Irrigator-Aspirator (RIA) at a diameter of 1.5 mm larger than isthmus
Number of subjects: 45
Study 33051075 — intervention group
Group type: COMPARATOR
Intervention: Contralateral femur left intact without reaming
Number of subjects: 45
Study 35199478 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of esaxerenone and SGLT2 inhibitor
Number of subjects: 0
Study 35199478 — intervention group
Group type: EXPERIMENTAL
Intervention: Esaxerenone
Number of subjects: 0
Study 35199478 — intervention group
Group type: COMPARATOR
Intervention: SGLT2 inhibitor
Number of subjects: 0
Study 35199478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34221093 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic Breathing (RB) performed every 12 hours for three consecutive days after surgery
Number of subjects: 60
Study 34221093 — intervention group
Group type: COMPARATOR
Intervention: Routine care (opioid analgesics) with no additional interventions
Number of subjects: 60
Study 35124234 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 574
Study 35124234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 574
Study 35259416 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 670
Study 35259416 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic cranial irradiation (no PCI)
Number of subjects: 670
Study 35259416 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI) with durvalumab
Number of subjects: 670
Study 35259416 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI) with fewer fractions
Number of subjects: 670
Study 35259416 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI) excluding indirect costs
Number of subjects: 670
Study 32438041 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling arm (vaginal self-sampling kit)
Number of subjects: 88
Study 32438041 — intervention group
Group type: COMPARATOR
Intervention: Control arm (encouraged to make an appointment for Pap smear)
Number of subjects: 88
Study 34312190 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA supplementation (sublingual or oral) at 50, 100 or 200 mg daily over 3 days
Number of subjects: 270
Study 34312190 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA supplementation
Number of subjects: 270
Study 34312190 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA supplementation (oral vs sublingual)
Number of subjects: 270
Study 32495381 — intervention group
Group type: EXPERIMENTAL
Intervention: 3MDR (multi-modular motion-assisted memory desensitization and reprocessing)
Number of subjects: 42
Study 34426064 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly group‐based diabetes self‐management education (DSME) and monthly vouchers ($28‐$140/month) redeemable for fruits and vegetables at local markets
Number of subjects: 97
Study 32987647 — intervention group
Group type: EXPERIMENTAL
Intervention: Colostrum (2 × 500 mg) harvested at 2 hours after delivery
Number of subjects: 31
Study 32987647 — intervention group
Group type: EXPERIMENTAL
Intervention: Colostrum (2 × 500 mg) harvested at 24 hours after delivery
Number of subjects: 31
Study 32987647 — intervention group
Group type: COMPARATOR
Intervention: Colostrum (2 × 500 mg) harvested at 72 hours after delivery
Number of subjects: 31
Study 32987647 — intervention group
Group type: COMPARATOR
Intervention: Placebo (whey)
Number of subjects: 31
Study 34287475 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengzhan Shengmai capsule 0.36 g three times a day
Number of subjects: 294
Study 34287475 — intervention group
Group type: COMPARATOR
Intervention: Donepezil hydrochloride 5 mg once a day
Number of subjects: 294
Study 34601649 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps tendon graft with bone block (BT)
Number of subjects: 40
Study 34601649 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-patellar tendon-bone graft (BTB)
Number of subjects: 40
Study 34596269 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intramuscular testosterone treatment (1 mg/kg/month)
Number of subjects: 28
Study 34596269 — intervention group
Group type: COMPARATOR
Intervention: Per oral letrozole treatment (2.5 mg/day)
Number of subjects: 28
Study 33064410 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress measured via salivary cortisol and testosterone
Number of subjects: 25
Study 33064410 — intervention group
Group type: EXPERIMENTAL
Intervention: Pupillometry measuring left eye pupil constriction
Number of subjects: 25
Study 33064410 — intervention group
Group type: EXPERIMENTAL
Intervention: Pupil constriction latency
Number of subjects: 25
Study 33064410 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone and pupil constriction latency
Number of subjects: 25
Study 33064410 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormones with left eye pupil constriction difference
Number of subjects: 25
Study 33064410 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone-to-cortisol ratio decline with left eye pupil constriction
Number of subjects: 25
Study 33064410 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone-to-cortisol ratio decline and somatosensory processing
Number of subjects: 25
Study 35999317 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomosis (IIA)
Number of subjects: 140
Study 32915354 — intervention group
Group type: EXPERIMENTAL
Intervention: RECALL (Reading to Engage Children with Autism in Language and Learning)
Number of subjects: 31
Study 32915354 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 31
Study 32933509 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial of labor after cesarean (TOLAC)
Number of subjects: 708
Study 32933509 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model for VBAC success
Number of subjects: 708
Study 32933509 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision curve analysis of the predictive model
Number of subjects: 708
Study 34666139 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation (CBA)
Number of subjects: 203
Study 34666139 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drug (AAD) therapy
Number of subjects: 203
Study 33015912 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day low-residue diet (LRD) with standard laxative treatment
Number of subjects: 855
Study 33015912 — intervention group
Group type: COMPARATOR
Intervention: 3-day low-residue diet (LRD) with standard laxative treatment
Number of subjects: 855
Study 33015912 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day low-residue diet (LRD)
Number of subjects: 855
Study 33015912 — intervention group
Group type: COMPARATOR
Intervention: 3-day low-residue diet (LRD)
Number of subjects: 855
Study 34655400 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium L‐threonate (MLT) for 12 weeks
Number of subjects: 4
Study 34655400 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐dose intravenous (IV) magnesium sulfate (MgSO4) for 3 days followed by open‐label MLT for 24 weeks
Number of subjects: 4
Study 34655400 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro magnesium supplementation experiments in cells from 14 XMEN patients
Number of subjects: 4
Study 34865624 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid clinical trial procedures using a mobile app for symptom recording and home-collected nasal swabs.
Number of subjects: 99
Study 33106853 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational analysis; 1 kg/m2 increase in BMI
Number of subjects: 460397
Study 33106853 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational analysis; 1 µg/mL increase in plasma adiponectin
Number of subjects: 460397
Study 33106853 — intervention group
Group type: EXPERIMENTAL
Intervention: One-sample Mendelian randomization; 1 kg/m2 genetically determined increase in BMI
Number of subjects: 460397
Study 33106853 — intervention group
Group type: EXPERIMENTAL
Intervention: One-sample Mendelian randomization; 1 µg/mL genetically determined increase in plasma adiponectin
Number of subjects: 460397
Study 33106853 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-sample Mendelian randomization; corresponding estimates for BMI
Number of subjects: 460397
Study 33106853 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-sample Mendelian randomization; corresponding estimates for adiponectin
Number of subjects: 460397
Study 36261813 — intervention group
Group type: EXPERIMENTAL
Intervention: HJD Formula Granules plus lifestyle intervention
Number of subjects: 183
Study 36261813 — intervention group
Group type: EXPERIMENTAL
Intervention: HJD Elixation plus lifestyle intervention
Number of subjects: 183
Study 36261813 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus lifestyle intervention
Number of subjects: 183
Study 34733625 — intervention group
Group type: EXPERIMENTAL
Intervention: 22G needle
Number of subjects: 102
Study 34733625 — intervention group
Group type: COMPARATOR
Intervention: 25G needle
Number of subjects: 102
Study 35488724 — intervention group
Group type: EXPERIMENTAL
Intervention: Synovial fluid IL-6 concentrations
Number of subjects: 23
Study 35488724 — intervention group
Group type: EXPERIMENTAL
Intervention: Synovial fluid CTX-II concentrations
Number of subjects: 23
Study 35488724 — intervention group
Group type: EXPERIMENTAL
Intervention: Synovial fluid IL-1ß concentrations
Number of subjects: 23
Study 33496964 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttreatment reductions in WHO drinking risk levels
Number of subjects: 693
Study 32641096 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior colporraphy
Number of subjects: 0
Study 32641096 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal patch plastron
Number of subjects: 0
Study 34962022 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-nurse collaboration (specifically conflict management subscale)
Number of subjects: 155
Study 34962022 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-perceived job performance
Number of subjects: 155
Study 34468881 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial invasive revascularization strategy with optimal medical therapy
Number of subjects: 0
Study 34468881 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 0
Study 35466074 — intervention group
Group type: EXPERIMENTAL
Intervention: Syndactylia
Number of subjects: 40
Study 35466074 — intervention group
Group type: COMPARATOR
Intervention: Closed reduction and intrinsic plus cast immobilisation
Number of subjects: 40
Study 35377706 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg daily
Number of subjects: 530
Study 35377706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 530
Study 33964566 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic self-disclaimer caption
Number of subjects: 311
Study 33964566 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific self-disclaimer caption
Number of subjects: 311
Study 33964566 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning self-disclaimer caption
Number of subjects: 311
Study 33964566 — intervention group
Group type: COMPARATOR
Intervention: No caption (control group)
Number of subjects: 311
Study 32512985 — intervention group
Group type: EXPERIMENTAL
Intervention: Home bleaching
Number of subjects: 60
Study 32512985 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser bleaching
Number of subjects: 60
Study 32512985 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma arc bleaching
Number of subjects: 60
Study 32512985 — intervention group
Group type: EXPERIMENTAL
Intervention: No light source in-office bleaching
Number of subjects: 60
Study 36339195 — intervention group
Group type: EXPERIMENTAL
Intervention: Everyday discrimination during the pandemic
Number of subjects: 165
Study 36339195 — intervention group
Group type: EXPERIMENTAL
Intervention: Everyday discrimination before the pandemic
Number of subjects: 165
Study 36339195 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support and social cohesion during the pandemic
Number of subjects: 165
Study 33185602 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired PLIÉ program (1 hour, 2 days/week, 12 weeks, 3 home visits)
Number of subjects: 30
Study 616401931 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic diet guidance
Number of subjects: 112
Study 616401931 — intervention group
Group type: COMPARATOR
Intervention: Routine diet guidance
Number of subjects: 112
Study 37212758 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 466
Study 37212758 — intervention group
Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 466
Study 33326255 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab, lenalidomide, and dexamethasone (D‐Rd)
Number of subjects: 737
Study 33326255 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide and dexamethasone (Rd)
Number of subjects: 737
Study 32359899 — intervention group
Group type: EXPERIMENTAL
Intervention: ticagrelor + aspirin
Number of subjects: 500
Study 32359899 — intervention group
Group type: COMPARATOR
Intervention: aspirin
Number of subjects: 500
Study 35229778 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual toothbrush (Oral‐B Pro Health Gum care®)
Number of subjects: 60
Study 35229778 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered toothbrush (Oral‐B Cross action Power Dual®)
Number of subjects: 60
Study 35229778 — intervention group
Group type: EXPERIMENTAL
Intervention: Charcoal toothbrush (Colgate slim Soft Charcoal®)
Number of subjects: 60
Study 35229778 — intervention group
Group type: COMPARATOR
Intervention: All toothbrushes
Number of subjects: 60
Study 32010948 — intervention group
Group type: EXPERIMENTAL
Intervention: Online interactive presentation formats (experimental condition)
Number of subjects: 1531
Study 32010948 — intervention group
Group type: COMPARATOR
Intervention: Control condition (receiving no information)
Number of subjects: 1531
Study 32010948 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition
Number of subjects: 1531
Study 32010948 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1531
Study 32020676 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (INT)
Number of subjects: 28
Study 32020676 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Continuous Training (CONT)
Number of subjects: 28
Study 32020676 — intervention group
Group type: EXPERIMENTAL
Intervention: Both INT and CONT
Number of subjects: 28
Study 35778941 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral-based physical therapy (CBPT) intervention, 6 sessions, telephone-based
Number of subjects: 112
Study 34691747 — intervention group
Group type: EXPERIMENTAL
Intervention: Arpeggiated guitar pattern
Number of subjects: 180
Study 34691747 — intervention group
Group type: COMPARATOR
Intervention: Bass/chord guitar pattern
Number of subjects: 180
Study 34691747 — intervention group
Group type: EXPERIMENTAL
Intervention: Both accompaniment patterns
Number of subjects: 180
Study 35906549 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 30 Gy/5fx HSRT and 20 Gy/10fx IMRT with concurrent temozolomide and adjuvant chemotherapy
Number of subjects: 0
Study 34192938 — intervention group
Group type: EXPERIMENTAL
Intervention: Largest possible modular femoral head (36 mm to 44 mm)
Number of subjects: 96
Study 34192938 — intervention group
Group type: COMPARATOR
Intervention: 32 mm head
Number of subjects: 96
Study 32869579 — intervention group
Group type: EXPERIMENTAL
Intervention: MHF-like needling technique combined with Tuina manipulation
Number of subjects: 72
Study 32869579 — intervention group
Group type: COMPARATOR
Intervention: Conventional needling
Number of subjects: 72
Study 36078655 — intervention group
Group type: EXPERIMENTAL
Intervention: Mostly Nonlinear (MNL; 20% linear, 80% nonlinear)
Number of subjects: 183
Study 36078655 — intervention group
Group type: EXPERIMENTAL
Intervention: Mostly Linear (ML; 80% linear, 20% nonlinear)
Number of subjects: 183
Study 36078655 — intervention group
Group type: COMPARATOR
Intervention: Control (C; conventional teaching from generalists)
Number of subjects: 183
Study 32906135 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard blood pressure treatment arm
Number of subjects: 2428
Study 32906135 — intervention group
Group type: COMPARATOR
Intervention: Intensive blood pressure treatment arm
Number of subjects: 2428